MacroGenics and Takeda enter alliance to develop multiple additional DART therapeutics
MacroGenics and Takeda announced a collaboration agreement to develop and commercialize up to four product candidates. Each of these product candidates will be directed against jointly selected pairs of molecular targets and incorporate MacroGenics' Dual-Affinity Re-Targeting proprietary platform. September 29, 2014